The combined oral contraceptive pill containing drospirenone and ethinyl estradiol plus levomefolate calcium

  title={The combined oral contraceptive pill containing drospirenone and ethinyl estradiol plus levomefolate calcium},
  author={Rachel B. Rapkin and Mitchell D. Creinin},
  journal={Expert Opinion on Pharmacotherapy},
  pages={2403 - 2410}
  • R. RapkinM. Creinin
  • Published 15 September 2011
  • Medicine, Biology
  • Expert Opinion on Pharmacotherapy
Introduction: Neural tube defects are the second most common congenital anomaly in the United States, although their incidence may be decreased by periconception folic acid supplementation. A new oral contraceptive containing drospirenone and ethinyl estradiol plus levomefolate calcium was formulated to decrease the risk of neural tube defects in pregnancies conceived while taking or shortly after discontinuing this pill. Areas covered: Because of its novelty, very few studies have been… 

Efficacy and bleeding profile of a combined oral contraceptive containing oestradiol valerate/dienogest: A pooled analysis of three studies conducted in North America and Europe

E2V/DNG provides reliable contraceptive efficacy in women aged 18 to 50 years, and in the first 13 cycles of treatment, 76 to 81% of women experienced scheduled withdrawal bleeding, and 13 to 23% experienced intracyclic bleeding.

Simultaneous Quantification of Drospirenone, Ethinyl Estradiol and Levomefolate by Stability Indicating RP-HPLC Method

The developed and validated liquid chromatographic method is able to quantify the drospirenone, ethinyl estradiol and levomefolate in the presence of degradation products.

Optimization of HPLC Method Using Central Composite Design for the Estimation of Escitalopram and L-Methyl Folate

Statistical design (Central Composite Design) was employed to develop an accurate and precise reverse phase high performance liquid chromatography (RP-HPLC) method for the simultaneous estimation of



Efficacy of a New Low-Dose Oral Contraceptive With Drospirenone in Premenstrual Dysphoric Disorder

A 24/4 regimen of drospirenone 3 mg and ethinyl estradiol 20 &mgr;g improves symptoms associated with premenstrual dysphoric disorder.

Risk of Thromboembolism in Women Taking Ethinylestradiol/Drospirenone and Other Oral Contraceptives

Ethinylestradiol/drospirenone initiators and initiators of other oral contraceptives are similarly likely to experience thromboembolism.

A combined oral contraceptive containing 3-mg drospirenone/ 20-microg ethinyl estradiol in the treatment of acne vulgaris: a randomized, double-blind, placebo-controlled study evaluating lesion counts and participant self-assessment.

The COC 3-mg DRSP/20-microg EE 24/4 regimen COC is a suitable option for women with moderate acne vulgaris who require contraception.

Drospirenone: pharmacology and pharmacokinetics of a unique progestogen.

The use of newer progestins for contraception.

Risk of hyperkalemia in women taking ethinylestradiol/drospirenone and other oral contraceptives.

Treatment of Acne Using a 3-Milligram Drospirenone/20-Microgram Ethinyl Estradiol Oral Contraceptive Administered in a 24/4 Regimen: A Randomized Controlled Trial

The low-dose combined oral contraceptive containing 3-mg drospirenone/20-microgram ethinyl estradiol administered in a 24/4 regimen significantly reduced acne lesion counts more effectively than placebo and demonstrated greater improvement in the Investigator Static Global Assessment rating of acne.